Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Response to gastroesophageal reflux disease therapy: assessment at 4 weeks predicts response/non-response at 8 weeks.

Kusano M, Hongo M, Miwa H.

Digestion. 2012;85(4):282-7. doi: 10.1159/000336715. Epub 2012 Apr 21.

PMID:
22538343
2.

Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.

Hongo M, Miwa H, Kusano M; J-FAST group.

J Gastroenterol Hepatol. 2012 May;27(5):913-8. doi: 10.1111/j.1440-1746.2011.07042.x.

PMID:
22142515
3.

Effect of rabeprazole treatment on health-related quality of life and symptoms in patients with reflux esophagitis: a prospective multicenter observational study in Japan.

Hongo M, Miwa H, Kusano M; J-FAST Group.

J Gastroenterol. 2011 Mar;46(3):297-304. doi: 10.1007/s00535-010-0342-1. Epub 2010 Nov 17.

PMID:
21082202
4.

Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.

Furuta T, Shimatani T, Sugimoto M, Ishihara S, Fujiwara Y, Kusano M, Koike T, Hongo M, Chiba T, Kinoshita Y; Acid-Related Symptom Research Group.

J Gastroenterol. 2011 Nov;46(11):1273-83. doi: 10.1007/s00535-011-0446-2. Epub 2011 Aug 24.

PMID:
21861141
5.

Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.

Komatsu-Tanaka M, Iwakiri R, Fujimoto K, Fujiwara Y, Inamori M, Tanaka J, Shimatani T, Akiyama J, Ando T, Manabe N, Kinjo F, Deguchi R, Kusano M.

Dig Endosc. 2012 Nov;24(6):407-11. doi: 10.1111/j.1443-1661.2012.01301.x. Epub 2012 Apr 8.

PMID:
23078431
6.

Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?

Takeuchi T, Oota K, Harada S, Edogawa S, Kojima Y, Sanomura M, Sakaguchi M, Hayashi K, Hongoh Y, Itabashi T, Kitae H, Hoshimoto M, Takeuchi N, Higuchi K.

Intern Med. 2015;54(2):97-105. doi: 10.2169/internalmedicine.54.3412. Epub 2015 Jan 15.

7.

The impact of lifestyle modification on the health-related quality of life of patients with reflux esophagitis receiving treatment with a proton pump inhibitor.

Kinoshita Y, Ashida K, Miwa H, Hongo M.

Am J Gastroenterol. 2009 May;104(5):1106-11. doi: 10.1038/ajg.2009.77. Epub 2009 Mar 31.

PMID:
19337239
8.

Possible etiology of improvements in both quality of life and overlapping gastroesophageal reflux disease by proton pump inhibitor treatment in a prospective randomized controlled trial.

Mönnikes H, Schwan T, van Rensburg C, Straszak A, Theek C, Lühmann R, Sander P, Tholen A.

BMC Gastroenterol. 2013 Oct 1;13:145. doi: 10.1186/1471-230X-13-145.

9.

Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.

Tominaga K, Iwakiri R, Fujimoto K, Fujiwara Y, Tanaka M, Shimoyama Y, Umegaki E, Higuchi K, Kusano M, Arakawa T; GERD 4 Study Group.

J Gastroenterol. 2012 Mar;47(3):284-92. doi: 10.1007/s00535-011-0488-5. Epub 2011 Nov 15.

PMID:
22081052
10.

Lifestyle factors affecting gastroesophageal reflux disease symptoms: a cross-sectional study of healthy 19864 adults using FSSG scores.

Yamamichi N, Mochizuki S, Asada-Hirayama I, Mikami-Matsuda R, Shimamoto T, Konno-Shimizu M, Takahashi Y, Takeuchi C, Niimi K, Ono S, Kodashima S, Minatsuki C, Fujishiro M, Mitsushima T, Koike K.

BMC Med. 2012 May 3;10:45. doi: 10.1186/1741-7015-10-45.

11.

Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole.

Muro Y, Sugiura K, Nitta Y, Mitsuma T, Hoshino K, Usuda T, Hayashi K, Murase Y, Shimizu M, Matsuo H.

Clin Exp Rheumatol. 2009 May-Jun;27(3 Suppl 54):15-21.

PMID:
19796556
12.

Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease.

Becher A, El-Serag H.

Aliment Pharmacol Ther. 2011 Sep;34(6):618-27. doi: 10.1111/j.1365-2036.2011.04774.x. Epub 2011 Jul 20. Review.

13.

Endoscopic grading of gastroesophageal flap valve helps predict proton pump inhibitor response in patients with gastroesophageal reflux disease.

Cheong JH, Kim GH, Lee BE, Choi MK, Moon JY, Ryu DY, Kim DU, Song GA.

Scand J Gastroenterol. 2011 Jul;46(7-8):789-96. doi: 10.3109/00365521.2011.579154. Epub 2011 May 26.

PMID:
21615222
14.
15.

The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease.

Taketani H, Sumida Y, Tanaka S, Imajo K, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Kanemasa K, Chayama K, Itoh Y, Yoshikawa T, Saibara T, Fujimoto K, Nakajima A; Japan Study Group of NAFLD.

J Gastroenterol. 2014 Jul;49(7):1163-74. doi: 10.1007/s00535-013-0871-5. Epub 2013 Aug 22.

PMID:
23975270
16.

[The quality of life dynamics in patients with gastroesophageal reflux disease during rabeprazol therapy].

Maev IV, Samsonov AA, Odintsova AN, Golubev NN, Iablunovskaia GI.

Eksp Klin Gastroenterol. 2009;(4):97-100. Russian.

PMID:
19967818
17.

Gastroesophageal reflux disease as an etiology of sleep disturbance in subjects with insomnia and minimal reflux symptoms: a pilot study of prevalence and response to therapy.

Shaheen NJ, Madanick RD, Alattar M, Morgan DR, Davis PH, Galanko JA, Spacek MB, Vaughn BV.

Dig Dis Sci. 2008 Jun;53(6):1493-9.

PMID:
17985241
18.

Sleep dysfunction in Japanese patients with gastroesophageal reflux disease: prevalence, risk factors, and efficacy of rabeprazole.

Fujiwara Y, Kohata Y, Kaji M, Nebiki H, Yamasaki T, Sasaki E, Hayakawa T, Machida H, Tanigawa T, Watanabe K, Watanabe T, Tominaga K, Arakawa T.

Digestion. 2010;81(3):135-41. doi: 10.1159/000253849. Epub 2010 Jan 14.

PMID:
20090330
19.

Combination of angiotensin II receptor blockers promotes proton pump inhibitor-based healing of reflux esophagitis.

Miwa H, Hongo M, Kusano M; J-FAST Group.

J Gastroenterol. 2012 Mar;47(3):249-55. doi: 10.1007/s00535-011-0479-6. Epub 2011 Nov 1.

PMID:
22041918
20.

Characteristics affecting health-related quality of life (HRQOL) in Japanese patients with reflux oesophagitis and the effect of lansoprazole on HRQOL.

Hongo M, Kinoshita Y, Miwa H, Ashida K.

J Med Econ. 2009 Sep;12(3):182-91. doi: 10.3111/13696990903227739.

PMID:
19691444
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk